Healthy Extracts Reports Third Quarter 2023 Results
November 15, 2023Net Revenue up 23%, with Strong Subscription-Based Revenue GrowthLAS VEGAS, Nov. 14, 2023 (GLOBE NEWSWIRE) — Healthy Extracts Inc. (OTCQB: HYEX), a platform for acquiring, developing, patenting, marketing, and distributing plant-based nutraceuticals that target select high-growth categories within the multibillion-dollar nutraceuticals market, reported results for the three and nine months ended September 30, 2023. All comparisons are to the year-ago period unless otherwise noted. Financial & Operational Highlights Net revenue increased 23% to $614,000 in the third quarter of 2023 and was up 27% to $1.8 million for the first nine months of 2023, driven by product line and distribution channel expansion, as well as growth in subscription-based revenue.Gross margin improved to 80.4% in the third quarter from 48.4% in the previous quarter due to a favorable shift to higher margin sales.Net loss in Q3 totaled $248,000 or $(0.00) per basic and diluted share, primarily due to one-time costs associated with the company’s previously announced acquisition and related planned public offering and uplist to a major exchange, interest expense, and stock-based compensation expense (comprised of options and warrants). This compares to net loss of $170,000 or $(0.00) per basic and diluted share in the same year-ago quarter.Net income totaled $33,000 or $0.00 per share after excluding the costs associated with the company’s planned acquisition and public offering expenses, regulatory expense, stock-based compensation expense (comprised of options and warrants), the change in fair value on derivative expense, and interest expense.Direct-to-consumer subscription customers at September 30, 2023 increased 37% versus September 30, 2022, driving a 26% increase in subscription-based revenue for the first nine months of the year. Amazon “Subscribe & Save” customers at September 30, 2023 increased 55% versus September 30, 2022, driving 25% increase in subscription-based revenue for the first nine months of the year. Subscription growth is valuable since it helps reduce customer acquisition costs, increases traction, and provides greater visibility into future revenue.Officially launched BergametNA’s Sleep Breathing Support, a natural supplement designed to improve sleep apnea and support more restful sleep, with strong initial sales. Management Commentary “In Q3, we continued to grow our top-line at a healthy double-digit pace as our product offerings, customer subscriptions, and distribution channels continued to expand,” commented Healthy Extracts president, Duke Pitts. “We also returned to normal margins of more than 80% due to improved manufacturing efficiencies and lower freight costs implemented in Q2. “The efficiencies implemented helped us generate profitability when excluding non-cash expenses and certain one-time adjustments, such as those related to our previously announced planned acquisition and related public offering expenses. “Our expanded product offerings included the full official launch our BergametNA’s Sleep Breathing Support, a natural supplement designed to improve sleep apnea by accentuating the ability of the brain to communicate with the diaphragm and support more restful sleep. Given the better-than-anticipated initial sales of this new product, it is on track to become one of our best sellers in 2024. “Next up is our launch of LONGEVITY, a proprietary formulation designed to support arterial flexibility, anti-aging, cellular and joint health. Its unique formulation is designed to boost blood flow and circulation, slow the effects of aging, and reduce the deleterious effects of misplaced calcium in the body. We’re currently on track to launch LONGEVITY before the end of the year. “Our top brand ambassador and renowned fitness expert, Whitney Johns, is preparing to launch WHITNEY JOHNS™ NUTRITION on-the-go gel packs for GUT HEALTH and COLLAGEN (anti-aging) in early 2024. They are based on our exclusive Healthy Extracts delivery system and formulations. “We also plan to soon introduce MYNUS sugar blocker, which is specially formulated to reduce up to 42% of the sugar impact from meals. MYNUS is an on-the-go gel-pack which will be available under our exclusive U.S. and Canadian licensing and manufacturing agreement with Gelteq featuring their advanced gel technology. We plan to launch these new gel-packs in the first quarter of next year. “We anticipate these new products will continue to help drive growth and market expansion as they leverage our multiple sales and distribution channels and existing customer base. As with all of our products, they will incorporate plant-based proprietary and patented ingredients supported by independent published research. “As we complete the year and prepare for 2024, we will continue to focus on expanding our recurring revenue streams and growing our customer base, while maintaining our traditional gross margins. We will continue to pursue strategic acquisitions that would further enhance our plant-based portfolio and build upon the successful acquisitions of BergametNA™ for heart health and Ultimate Brain Nutrients™ for brain health. “We believe our strengthening results this year demonstrate we have built a solid platform for ongoing growth and expanding our presence across the various markets we serve. We see this keeping us on pace for another record year and providing favorable momentum going into 2024.” Q3 Financial Summary Net revenue in the third quarter of 2023 increased 23% to $614,000 from $500,000 in the same year-ago quarter, primarily due to product line and distribution channel expansion. Gross profit totaled $493,000 or 80.4% of net revenue as compared to $285,000 or 48.4% of net revenue in the previous quarter and $431,000 or 86.3% of net revenue in the same year-ago quarter. The decrease in gross margin compared to the year-ago period was a result of the increase in manufacturing and freight costs which have subsequently normalized. Operating expenses increased $268,000 to $754,000 compared to the same year-ago quarter. The increase in operating expenses was due to the costs involved in the on-going efforts in the acquisitions and planned public offering and uplist, and stock-based compensation expense (comprised of options and warrants). Net loss totaled $248,000 or $(0.00) per basic and diluted share compared to a net loss of $170,000 or $(0.00) per basic and diluted share in the same year-ago quarter. The increased net loss was primarily due to one-time costs associated with the company’s previously announced acquisition and related planned public offering and uplist to a major exchange, increased manufacturing and freight costs, interest expense, and stock-based compensation expense (comprised of options and warrants). Excluding costs related to the company’s planned acquisition and public offering expenses, regulatory expense, stock-based compensation expense (comprised of options and warrants), change in fair value on derivative expense and interest expense, net income totaled $33,000. Cash totaled $46,000 as of September 30, 2023, compared to $92,500 on June 30, 2023. First Nine Months 2023 Financial Summary Net revenue in the first nine months of 2023 increased 27% to $1.8 million from $1.4 million in the same year-ago period, primarily due to product line and distribution channel expansion. Gross profit totaled $1.1 million or 58.1% of net revenue as compared to $1.0 million or 71.9% of net revenue in the same year-ago period. The decrease in gross margin was a result of increased manufacturing and freight costs during the earlier part of the year, with these factors improving in the third quarter. Operating expenses, excluding the costs involved in the on-going efforts in the acquisitions, planned public offering and uplist to a major exchange and stock compensation expense, decreased $211,000 to $1.5 million compared to the same year-ago period. The decrease in operating expenses was due to a reduction in general and administrative expenses. Net loss totaled $2.1 million or $(0.01) per basic and diluted share, as compared to a net loss of $1.0 million or $(0.00) per basic and diluted share in the same year-ago period. Excluding costs related to the company’s planned acquisition and public offering expenses, regulatory expense, stock-based compensation expense (comprised of options and warrants), change in fair value on derivative expense and interest expense, net loss in the first nine months of 2023 totaled $477,000 or ($0.00) per basic and diluted share. About Healthy Extracts “Live Life Young Again” Healthy Extracts Inc. is a platform for acquiring, developing, researching, patenting, marketing, and distributing plant-based nutraceuticals. The company’s subsidiaries, BergametNA™ and Ultimate Brain Nutrients™ (UBN), offer nutraceutical natural heart and brain health supplements. This includes the only heart health supplement distributed in North America containing Citrus Bergamot SuperFruit™. This superfruit has the highest known concentration of polyphenols and flavonoids. UBN’s KETONOMICS® proprietary formulations, which have been designed to enhance brain activity, focus, headache and cognitive behavior, provide many sales and intellectual property licensing opportunities. For more information visit: healthyextractsinc.com, bergametna.com or tryubn.com. Forward-Looking Statements and Safe Harbor Notice All statements other than statements of historical facts included in this press release are “forward-looking statements” (as defined in the Private Securities Litigation Reform Act of 1995). Such forward-looking statements include our expectations and those statements that use forward-looking words such as “projected,” “expect,” “possibility” and “anticipate.” The achievement or success of the matters covered by such forward-looking statements involve significant risks, uncertainties and assumptions. Actual results could differ materially from current projections or implied results. Investors should read the risk factors set forth in the Company’s Annual Report on Form 10-K filed with the SEC on March 31, 2023, and future periodic reports filed with the SEC. All of the Company’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The Company cautions that statements and assumptions made in this news release constitute forward-looking statements and make no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. The information set forth herein speaks only as of the date hereof. The Company and its management undertake no obligation to revise these statements following the date of this news release. Food & Drug Administration Disclosure The product and formulation featured in this release is not for use by or sale to persons under the age of 12. This product should be used only as directed on the label. Consult with a physician before use if you have a serious medical condition or use prescription medications. A doctor’s advice should be sought before using this and any supplemental dietary product. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure or prevent any disease. BergametNA™, Ultimate Brain Nutrients™, UBN™, Citrus Bergamot SuperFruit™ and F4T® are registered trademarks of Healthy Extracts Inc.™ Company ContactDuke Pitts, PresidentHealthy Extracts Inc.Tel (720) 463-1004Email contact Investor ContactRonald Both CMA Investor RelationsTel (949) 432-7566Email contact Media Contact:Tim RandallCMA Media RelationsTel (949) 432-7572Email Contact HEALTHY EXTRACTS, INC. CONSOLIDATED STATEMENT OF OPERATIONS FOR THE THREE AND NINE MONTHS ENDING SEPTEMBER 30, 2023 AND 2022 (Unaudited) FOR THE 3 MONTHS ENDING FOR THE 9 MONTHS ENDING SEPTEMBER 30 SEPTEMBER 30 2023 2022 2023 2022 REVENUE Revenue $613,541 $499,653 $1,816,968 $1,432,850 Net revenue 613,541 499,653 1,816,968 1,432,850 COST OF REVENUE Cost of goods sold 120,309 68,551 760,825 402,788 Total cost of revenue 120,309 68,551 760,825 402,788 GROSS PROFIT 493,233 431,102 1,056,143 1,030,062 OPERATING EXPENSES General and administrative 754,026 485,568 2,977,998 1,744,326 Total operating expenses 754,026 485,568 2,977,998 1,744,326 OTHER INCOME (EXPENSE) Interest expense, net of interest income (24,502) (11,336) (138,774) (68,657)Change in fair value on derivative 37,371 (104,421) (33,687) (246,260)Gain on sale of asset – – – 2,643 Total other income (expense) 12,869 (115,757) (172,461) (312,274) Net income/(loss) before income tax provision (247,924) (170,223) (2,094,316) (1,026,538) NET INCOME/(LOSS) $(247,924) $(170,223) $(2,094,316) $(1,026,538) Income/(Loss) per share – basic and diluted $(0.00) $(0.00) $(0.01) $(0.00) Weighted average number of shares outstanding – basic and diluted 348,284,383 341,619,198 349,849,154 342,514,810 HEALTHY EXTRACTS, INC.CONSOLIDATED BALANCE SHEETSAS OF SEPTEMBER 30, 2023 AND DECEMBER 31, 2022(Unaudited) SEPTEMBER 30 DECEMBER 31, 2023 2022 ASSETS CURRENT ASSETS Cash $46,391 $65,651 Accounts receivable 109,224 105,794 Inventory, net 1,527,575 1,819,128 Offering costs 135,202 – Prepaid acquisition costs – 53,015 Right of use asset, net 86,279 – Total current assets 1,904,671 2,043,587 Fixed assets 3,855 5,501 Patents/Trademarks 521,881 521,881 Deposit 16,890 16,890 Goodwill 193,260 193,260 Total other assets 735,885 737,531 TOTAL ASSETS $2,640,556 $2,781,118 LIABILITIES AND STOCKHOLDERS’ EQUITY LIABILITIES Accounts payable $68,537 $91,316 Accrued liabilities 188,770 94,554 Lease liabilities – current 62,989 – Lease liabilities – long-term 26,187 – Notes payable 401,630 275,370 Notes payable – related party 83,366 866 Convertible debt, net of discount 595,638 317,284 Accrued interest payable 52,876 21,387 Accrued interest payable – related party 380 – Derivative liabilities 135,698 102,011 Total current and total liabilities 1,616,071 902,788 STOCKHOLDERS’ EQUITY Preferred stock, $0.001 par value, 75,000,000 shares authorized, none and none shares issued and outstanding, respectively – – Common stock, $0.001 par value, 2,500,000,000 shares authorized, 354,492,442 shares issued and outstanding as of September 30, 2023, and 345,172,442 shares issued and outstanding as of December 31, 2022, respectively 354,492 345,172 Additional paid-in capital 18,691,050 17,459,899 Accumulated deficit (18,021,058) (15,926,742)Total stockholders’ equity 1,024,485 1,878,330 TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $2,640,556 $2,781,118
